UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction | (Commission | (IRS Employer | ||
of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including
area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
On June 16, 2022, in the purported shareholder class action lawsuit captioned Liu et al. v. Intercept Pharmaceuticals, Inc. et al., case number 20-3488, the United States Court of Appeals for the Second Circuit entered a summary order affirming the order of the United States District Court for the Southern District of New York dated September 9, 2020.
In March 2020, the district court had dismissed the amended class action complaint (the “Complaint”) of the plaintiffs Liu et al., and on September 9, 2020, the district court denied the plaintiffs’ requests for reconsideration and for leave to amend their Complaint. The plaintiffs subsequently appealed the latter order, which has now been affirmed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTERCEPT PHARMACEUTICALS, INC. | ||
By: | /s/ Jerome Durso | |
Name: | Jerome Durso | |
Title: | President and CEO |
Date: June 21, 2022
Cover |
Jun. 16, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jun. 16, 2022 |
Entity File Number | 001-35668 |
Entity Registrant Name | Intercept Pharmaceuticals, Inc. |
Entity Central Index Key | 0001270073 |
Entity Tax Identification Number | 22-3868459 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 305 Madison Avenue |
Entity Address, City or Town | Morristown |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07960 |
City Area Code | 646 |
Local Phone Number | 747-1000 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | ICPT |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
)8F9WZDO+FKTJG$=;P@[H F-$ /17[(!J .[L4BSJ>A-0!T:;*O
MJO84N*?2K@#T&P3>I"2'N(86QS(PC>PC6B(Z:99K,F<2S;_?*+H%':C#E@G
MPPC<1+-GL,1DV-&PS>R!"I)/:=:0=U&DO)Q/"+O#J@Z?B/\Y8(09N'20]CZA
M=8B9BCBJ)'YPR>-AHF(!0I,E.Q,;)D+S?ATF&!ZSM&>>:=XO[:,]^$ IR'[E3:\N0%K
M117F7@?7N[6H9KN^FG'K*P-[OTR[OTBX61<0O
M6 ##O/[